



info@izocorp.com www.izocorp.com
#424, 800-15355 24th Ave. Surrey, BC V4A 2H9

NEWS RELEASE

IZOTROPIC ENGAGES CLINICAL RESEARCH ORGANIZATION IN PREPARATION FOR CLINICAL STUDY

VANCOUVER, BC - JULY 19, 2022 - Izotropic Corporation ("Izotropic" or the "**Company**") (CSE: **IZO**) (OTCQB: **IZOZF**) (FSE: **1R3**), a MedTech company commercializing IzoView, an advanced breast CT (computed tomography) imaging platform for the more accurate detection and diagnosis of breast cancer, announces it has engaged a world-leading clinical research organization (CRO) ICON plc ("ICON") to help prepare for its upcoming clinical study and submission for market authorization in the U.S.

With over 20 years of experience and having completed 500+ trials over the last five years, ICON's Medical Device team has been engaged to support multiple aspects of Izotropic's clinical research study including contracting, start-up, data collection and analysis, and report writing for FDA submission. ICON's senior experts work directly with the FDA, including the Division of Radiological Health.

"Engaging ICON means we are confidently moving forward with our business plans to bring IzoView to market efficiently," said Dr. John McGraw, CEO. "We plan to run a multi-site study with leading U.S. hospitals which will help to expedite patient recruitment and broadens the clinical experience with IzoView. When operating a multi-site study, it is critical that the same set of processes and procedures from start to finish are followed at each site for every patient to mitigate exclusion and maintain data integrity, and ICON's expertise enhances that capability."

About ICON plc

ICON is the world's leading clinical research organization, powered by healthcare intelligence. From molecule to medicine, ICON advances clinical research providing outsourced development and commercialization services to pharmaceutical, biotechnology, medical device, government, and public health organizations. ICON develop new innovations, drive emerging therapies forward, and improve patient

lives. With headquarters in Dublin, Ireland, ICON employ approximately 39,300 employees in 138 locations in 53 countries.

ON BEHALF OF THE BOARD

Investor Relations Contact:

James Berard

Email: jberard@izocorp.com

Cell: 778-228-2314

Toll Free: 1-833-IZOCORP ext.1

Media Inquiries Contact:

Jaclyn Thast

Email: jaclyn@izocorp.com

Toll Free: 1-833-IZOCORP ext.3

About Izotropic Corporation

Izotropic Corporation is the only publicly traded company commercializing a dedicated breast CT imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers. To expedite patient and provider access to IzoView, Izotropic's initial clinical study intends to demonstrate superior performance of diagnostic breast CT imaging over diagnostic mammography procedures. In follow-on clinical studies, Izotropic intends to validate platform applications, including breast screening in radiology, treatment planning and monitoring in surgical oncology, and breast reconstruction and implant monitoring in plastic and reconstructive surgery.

More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com.

Forward-Looking Statements

This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project,"

"target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These statements are not guarantees of performance and involve risks including those related to capital requirements, and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView is not yet approved for sale.